Company intelligence / Profile preview
Beijing Wehand-Bio Pharmaceutical Co., Ltd.
Beijing, Chinawehandbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has approved drugs in China (first approval in March 2020) and is conducting Phase 1 clinical trials for several compounds including a mulberry twig alkaloid for obesity and paclitaxel/WH-002 for HER2-negative breast cancer.
- Therapeutic areas
- OncologyEndocrinologyGastroenterologyNeurology
- Modalities
- Small molecule drugsHerbal medicine
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College
Beyond the preview
Go deeper on Beijing Wehand-Bio Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Wehand-Bio Pharmaceutical Co., Ltd..